Grace Therapeutics, Inc
gracetx.comWhat Do They Do?
Develops drug candidates for rare and orphan diseases, including an injectable nimodipine formulation for hospital use in aneurysmal subarachnoid hemorrhage.
10-K for FY2026, filed Jun 18, 2026We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes…View ↗
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address…View ↗
GTx-104 is designed to address significant unmet medical needs for patients with aSAH. We believe that with this novel nimodipine IV…View ↗
Who Are Their Customers?
The company identifies physicians and hospitals as potential users or beneficiaries of GTx-104 and surveyed hospital administrators and critical and neuro intensive care physicians involved in institutional purchasing decisions.
10-K for FY2026, filed Jun 18, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Aug 13, 2026
−$15.8MView ↗
- ▲ +370% (Loss)
- vs −$3.4M in Q1 FY2026
Pipeline focus
The older report deferred other candidates while prioritizing its lead candidate and said their development could resume with funding or partnerships; the latest says internal development funding will not resume under its current operating plan.
10-K for FY2023, filed Jun 23, 2023 10-K for FY2026, filed Jun 18, 2026In April 2023, we announced the strategic decision to prioritize development of GTX-104 with a goal to advance to commercialization, while…View ↗
In May 2023, we implemented a strategic realignment plan that resulted in engaging a new management team, streamlining our research and…View ↗
Loading...
